Reacta Biotech is develop, manufacture and commercialise oral food challenge materials to pharmaceutical standards.
Reacta Biotech has raised $3.7M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in November 2025.
Reacta Biotech's investors include Praetura Ventures, Development Bank of Wales, Perscitus LLP, Acceleris Capital, Jon Moulton’s family office.
Reacta Biotech is headquartered in Manchester, United Kingdom.
Reacta Biotech is develop, manufacture and commercialise oral food challenge materials to pharmaceutical standards.
Reacta Biotech is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Reacta Biotech — Funding & Investors." VCBacked, November 11, 2025, https://www.vcbacked.co/company/reacta-biotech. Accessed November 4, 2026.
VCBacked. (2025). Reacta Biotech — Funding & Investors. Retrieved November 4, 2026, from https://www.vcbacked.co/company/reacta-biotech
{{cite web |title=Reacta Biotech — Funding & Investors |url=https://www.vcbacked.co/company/reacta-biotech |website=VCBacked |access-date=November 4, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Reacta Biotech? Request a listing update